Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK biotech Antisoma has completed recruitment of patients into its phase II trial of AS1404 in ovarian cancer.
Subscribe to our email newsletter
The completion of enrollment keeps the company on course to report data from this trial during 2006.
Antisoma is currently conducting three separate phase II trials with AS1404 in lung, prostate and ovarian cancers. All evaluate the benefit of adding AS1404 to standard chemotherapy treatment.
“During this year, nearly 100,000 women will be diagnosed with ovarian cancer in Europe, North America and Japan. Many will receive platins and taxanes – drugs whose effects are greatly enhanced when combined with AS1404 in preclinical studies,” said Antisoma’s CEO, Glyn Edwards.
The trial includes around 70 patients from Europe, Australia and New Zealand with platinum-sensitive recurrent ovarian cancer. Half the patients are receiving standard chemotherapy treatment while the other half are receiving the same treatment plus AS1404.
The standard chemotherapy regime for these ovarian cancer patients is carboplatin and paclitaxel, the same as in the ongoing lung cancer study. Tumor response rates, time to tumor progression and survival will be compared to see whether patients on the AS1404-chemotherapy combination have better outcomes than those on chemotherapy alone.